Laseroptek Co. Ltd. Announces U.S. Launch of Pallas Solid-state UVB Medical Dermatology Laser

August 12, 2020

Laseroptek Co. Ltd., a developer and manufacturer of laser devices for aesthetic and medical dermatology, has announced the launch of its Pallas solid-state 311-nm UVB laser in the United States. The Pallas laser is FDA-cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma.
Pallas is the fifth Laseroptek laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world’s first solid-state UVB laser delivering efficacious and safe treatment for a variety of skin conditions that collectively affect close to a billion people worldwide.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical
    • Botox Cosmetic’s “The Confidence Collective” to Empower 250 Women Entrepreneurs
    • Medical Spa Show 2027 Call for Presentations Now Open
    • FDA Warning Letter to Texas Medical Spa Signals Increased Compliance Enforcement